Humanized Anti-CD79B Recombinant Antibody (clone Polatuzumab) (CAT#: TAB-897)

Figure 1 Shows endogenous B cell killing with anti-CD79b/CD3 TDB (T cell dependent bispecific) antibodies produced in either K&H format or as bisfabs (various anti- CD79b clones paired with anti-CD3 clone UCHT1 v9)

Figure 2 Shows B cell killing and T cell activation activity of bisfab anti- CD79b/CD3 (CD79b.A7/UCHT1 v9).

Figure 3 Shows monovalent or bivalent binding affinity of various clones of anti- CD79b measured by FACS.

Figure 4 FACS measures the binding affinity of various clones of anti-CD79b.

Bivalent binding affinity of anti-CD79b clones CD79b.F6 and CD79b.A7 comparing to monovalent binding of anti-CD79b clones CD79b.F6, CD79b.A7, and SN8v28 (as bisfab or K&H TDBs).

Figure 5 CD79B expression in DLBCL.

Immunohistochemical staining of a CD79B-positive DLBCL case with strong CD79B expression (H-score 300; case: DLBCL_63).

Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., ... & Dörken, B. (2015). Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia, 29(7), 1578-1586.

Figure 1 Anti-Human CD79B Recombinant Antibody (TAB-897) in WB

Western blot analysis of TAB-897 was performed by loading human CD79B protein, His tag.

Figure 2 Anti-Human CD79B Recombinant Antibody (TAB-897) in ELISA

ELISA analysis of TAB-897 was performed by coating with human CD79B protein (His tag). Then blocked with BSA and incubated with TAB-897. The HRP conjugated Anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.